DEA Rescheduling and 280E Tax Reform: Impact on Cannabis Businesses

Executive Summary

The Department of Justice's May 2026 rescheduling order moving cannabis from Schedule I to Schedule III of the Controlled Substances Act represents the most significant federal cannabis policy shift in five decades, with immediate and profound implications for Internal Revenue Code Section 280E tax treatment. Under current law, cannabis businesses cannot deduct ordinary business expenses because they traffic in Schedule I or II controlled substances. Rescheduling to Schedule III would eliminate this prohibition, potentially saving the industry $1.5 billion to $3 billion annually in federal tax liability. The order follows a multi-year administrative process initiated by President Biden in October 2022, involving Health and Human Services Department scientific review, Drug Enforcement Administration notice-and-comment rulemaking, and extensive public input. Medical cannabis operators, multi-state operators, and ancillary service providers now face a transformative tax landscape that will reshape capital allocation, pricing strategies, and competitive dynamics across state-legal markets. The effective date, implementation timeline, and potential legal challenges remain critical variables determining when operators can begin claiming standard business deductions.

Why This Matters

Rescheduling and 280E reform affect 15,000+ licensed cannabis businesses across 38 medical cannabis states, 24 adult-use jurisdictions, and approximately 428,000 industry employees, with direct financial impact on operators currently paying effective tax rates exceeding 70 percent. The stakes are measured in billions. According to the National Cannabis Industry Association, Section 280E currently costs state-legal cannabis businesses between $1.5 billion and $3 billion annually in additional federal tax burden. A typical dispensary with $5 million in annual revenue and $3.5 million in operating expenses currently pays federal tax on the full $5 million gross profit rather than the $1.5 million net income, resulting in tax bills that often exceed actual profits. Multi-state operators bear the heaviest burden. Publicly traded MSOs including Curaleaf, Trulieve, Green Thumb Industries, and Verano Holdings have reported effective tax rates between 60 and 85 percent in recent quarterly filings, compared to 21 percent corporate rates for non-cannabis businesses. Curaleaf reported $385 million in revenue for Q4 2025 but paid $89 million in federal taxes—a 23 percent rate on revenue rather than profit. Medical patients face indirect consequences through pricing. Industry analysts estimate that 280E compliance adds 15 to 25 percent to retail cannabis prices, as operators pass tax burdens to consumers. For patients using cannabis to manage chronic pain, epilepsy, PTSD, or chemotherapy side effects, this represents hundreds to thousands of dollars in annual out-of-pocket costs that insurance does not cover. State tax revenues also hang in the balance. States collected $3.7 billion in cannabis excise and sales taxes in 2025, according to the Marijuana Policy Project. Federal rescheduling could reduce wholesale prices by 20 to 30 percent as operators gain tax efficiency, potentially decreasing state tax collections by $500 million to $800 million annually unless states adjust their tax structures.

Background and History

The convergence of DEA rescheduling and Section 280E tax treatment traces back to the Controlled Substances Act of 1970 and the Tax Reform Act of 1982, creating a 44-year collision between federal drug policy and tax law that has defined the modern cannabis industry's financial structure.

The Controlled Substances Act Foundation (1970)

Congress enacted the Controlled Substances Act as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, establishing five schedules for controlled substances based on medical use, abuse potential, and safety. Cannabis was placed in Schedule I alongside heroin and LSD, defined as substances with no currently accepted medical use and high potential for abuse. The classification occurred despite the 1972 Shafer Commission recommendation that cannabis be decriminalized, and it has remained unchanged for 54 years. Schedule I designation carries severe legal consequences: federal criminal penalties for possession and distribution, prohibition on prescribing by physicians, and barriers to research. The classification also triggered tax implications that would not become apparent for another decade.

Section 280E Enactment (1982)

In 1982, Congress added Section 280E to the Internal Revenue Code in direct response to Jeffrey Edmondson, a Minneapolis cocaine and methamphetamine trafficker who successfully claimed business expense deductions for his drug operation in Tax Court. Edmondson v. Commissioner, 42 T.C.M. 1533 (1981), allowed deductions for telephone, packaging, and vehicle expenses used in his trafficking business. Congress responded swiftly. Section 280E states: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted." The legislative history makes clear that Congress intended to deny tax benefits to criminal enterprises. The House Report accompanying the provision stated it would prevent drug dealers from claiming "the same tax benefits as other business persons." No member of Congress in 1982 anticipated that states would begin legalizing cannabis for medical or adult use within 14 years.

California Proposition 215 and State-Legal Cannabis (1996-2012)

California voters approved Proposition 215, the Compassionate Use Act, in November 1996, becoming the first state to legalize medical cannabis. The law allowed patients with physician recommendations to possess and cultivate cannabis for conditions including cancer, AIDS, glaucoma, and chronic pain. Seven more states followed by 2000: Alaska, Oregon, Washington, Maine, Hawaii, Nevada, and Colorado. These early medical programs operated in legal gray zones. State law provided affirmative defense against state prosecution, but federal law remained unchanged. The Gonzales v. Raich Supreme Court decision in 2005 affirmed that Congress could regulate intrastate cannabis cultivation under the Commerce Clause, even for medical use complying with state law. The collision between state legalization and Section 280E began appearing in Tax Court in 2007. In Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner (CHAMP), 128 T.C. 173 (2007), the Tax Court held that a California medical cannabis dispensary could not deduct ordinary business expenses under Section 280E, even though it operated legally under state law. The court ruled that "trafficking" under 280E means engaging in commercial activity prohibited by the Controlled Substances Act, regardless of state law compliance.

The Cost of Goods Sold Workaround (2007-Present)

The CHAMP decision provided one critical exception: cannabis businesses could still deduct cost of goods sold (COGS) under Section 471, because Section 280E disallows "deductions" but COGS is technically a reduction in gross receipts, not a deduction. This distinction became the industry's primary tax planning strategy. Dispensaries and retailers, which purchase finished cannabis products and resell them, can deduct only the wholesale purchase price. Cultivators and manufacturers, which produce inventory, can capitalize additional costs into COGS including direct labor, materials, and certain overhead allocable to production facilities. This created a structural advantage for vertically integrated operators that could maximize COGS through cultivation and manufacturing operations. The IRS issued guidance in Chief Counsel Advice 201504011 (2015) clarifying that cannabis businesses must use inventory accounting methods and cannot deduct non-production expenses including rent for retail space, employee wages for budtenders, marketing, professional fees, or interest expense.

The Cole Memorandum Era (2013-2018)

Deputy Attorney General James Cole issued a memorandum in August 2013 establishing federal enforcement priorities for cannabis in states with regulatory frameworks. The Cole Memo stated that the Department of Justice would not prioritize enforcement against state-legal cannabis businesses that complied with state law and did not implicate federal priorities including distribution to minors, revenue to criminal enterprises, or diversion to prohibition states. The Cole Memo provided political cover for cannabis industry expansion but did not change Section 280E application. State-legal businesses continued paying effective tax rates of 60 to 80 percent throughout the Obama administration. Attorney General Jeff Sessions rescinded the Cole Memo in January 2018, creating renewed uncertainty, but enforcement patterns did not substantially change.

Congressional Reform Attempts (2019-2024)

Multiple bills to address Section 280E have been introduced since 2013. The Small Business Tax Equity Act, introduced by Representatives Earl Blumenauer and Carlos Curbelo in 2017 and reintroduced in subsequent Congresses, would amend Section 280E to exclude state-legal cannabis businesses. The bill has never received a floor vote in either chamber. The Marijuana Opportunity Reinvestment and Expungement (MORE) Act, which passed the House in 2020 and 2022, included Section 280E repeal as part of comprehensive cannabis descheduling. The bill died in the Senate both times. The Cannabis Administration and Opportunity Act, introduced by Senate Majority Leader Chuck Schumer in 2022, similarly included 280E reform but never advanced to a vote. By 2024, congressional gridlock made administrative rescheduling the most viable path to 280E relief.

Biden Administration Rescheduling Process (2022-2026)

President Biden issued a memorandum on October 6, 2022, directing Health and Human Services Secretary Xavier Becerra and Attorney General Merrick Garland to review cannabis scheduling "expeditiously." The memo cited "failed" federal cannabis policy and called for evidence-based classification. HHS initiated scientific review under the Controlled Substances Act's eight-factor analysis required by 21 U.S.C. § 811(c), evaluating cannabis's actual or relative potential for abuse, scientific evidence of pharmacological effect, current scientific knowledge, history and current pattern of abuse, scope and significance of abuse, and risk to public health. The Food and Drug Administration conducted the technical analysis. HHS delivered its recommendation to the DEA in August 2023, concluding that cannabis should be rescheduled to Schedule III based on accepted medical use and lower abuse potential than Schedule I or II substances. The recommendation remained confidential until Bloomberg Law obtained it through public records litigation in January 2024. The DEA published a Notice of Proposed Rulemaking in the Federal Register on May 21, 2024, formally proposing to reschedule cannabis to Schedule III. The 60-day comment period generated 43,000+ public submissions, making it one of the most-commented drug scheduling actions in DEA history. Comments ranged from medical associations supporting rescheduling based on therapeutic evidence to law enforcement groups opposing any schedule change and cannabis advocates arguing for complete descheduling. The DEA held a two-day public hearing in December 2024, hearing testimony from 58 witnesses including physicians, researchers, patients, industry representatives, and policy experts. Administrative Law Judge John Mulrooney presided over the hearing, which focused on the scientific evidence for medical use and abuse potential. The DEA issued its final rule on May 15, 2026, adopting the Schedule III classification with an effective date of July 1, 2026. The 45-day gap between publication and effectiveness allows for implementation planning and potential legal challenges.

Key Players

Drug Enforcement Administration

The DEA holds sole authority to schedule controlled substances under 21 U.S.C. § 811, making it the decisive actor in rescheduling. DEA Administrator Anne Milgram oversees the process, though the decision formally rests with the Attorney General. The agency's Diversion Control Division manages the administrative rulemaking process, while the Office of Chief Counsel handles legal analysis. The DEA has historically opposed cannabis rescheduling. The agency denied rescheduling petitions in 1972, 1995, 2001, 2006, and 2016, consistently maintaining that cannabis lacks accepted medical use and has high abuse potential. The 2026 decision represents a significant policy reversal driven by presidential directive and HHS scientific findings.

Department of Health and Human Services and FDA

HHS provides the scientific and medical evaluation that forms the basis for DEA scheduling decisions. The Food and Drug Administration conducted the eight-factor analysis, reviewing clinical trials, epidemiological data, pharmacology studies, and international evidence. FDA's conclusion that cannabis has "currently accepted medical use" for conditions including chronic pain, nausea, and appetite stimulation provided the scientific foundation for Schedule III classification. The FDA's analysis noted that 38 states have approved medical cannabis programs, over 3 million patients hold medical cannabis cards, and substantial clinical evidence supports therapeutic applications. The agency distinguished between FDA approval of specific drug products (which cannabis lacks) and "currently accepted medical use" under the Controlled Substances Act (which requires only qualified expert acceptance and available evidence).

Internal Revenue Service

The IRS enforces Section 280E through audits, assessments, and Tax Court litigation. The agency's Small Business/Self-Employed Division handles cannabis business examinations, applying heightened scrutiny to COGS calculations and expense classifications. IRS examination rates for cannabis businesses exceed 30 percent, compared to 0.4 percent for all businesses, according to industry tax practitioners. The IRS has issued limited formal guidance on 280E, relying primarily on Chief Counsel Advice memoranda and Tax Court precedent. The agency has consistently maintained that state law compliance is irrelevant to 280E application and that "trafficking" includes any commercial cannabis activity prohibited by federal law. Rescheduling to Schedule III will require IRS guidance on implementation timing, transition rules, and amended return procedures. The agency must clarify whether businesses can amend prior-year returns to claim refunds for years still open under the statute of limitations.

Multi-State Operators

Publicly traded MSOs stand to gain the most from 280E elimination. Curaleaf, the nation's largest cannabis operator with 151 dispensaries across 18 states, reported $1.3 billion in revenue for 2025 but paid $312 million in federal taxes—an effective rate of 24 percent on revenue. Curaleaf's Chief Financial Officer stated in the company's Q4 2025 earnings call that Schedule III rescheduling would reduce the company's effective tax rate from 75 percent to approximately 28 percent, adding $180 million to annual net income. Trulieve, the dominant operator in Florida with 185 dispensaries, reported similar tax burdens. Green Thumb Industries, Verano Holdings, Cresco Labs, and Ayr Wellness have all disclosed that 280E represents their single largest operating expense after cost of goods sold.

National Cannabis Industry Association

The NCIA, representing 1,800+ cannabis businesses, has advocated for 280E reform since its founding in 2010. The association submitted detailed comments during the DEA rulemaking process, documenting the tax burden's impact on small businesses, minority-owned operators, and medical access. NCIA estimates that 280E elimination would reduce cannabis prices by 15 to 20 percent within 18 months as operators gain tax efficiency and competition increases.

Smart Approaches to Marijuana

SAM, the leading organization opposing cannabis legalization, submitted comments urging the DEA to maintain Schedule I classification. The group argued that rescheduling would increase youth access, normalize cannabis use, and contradict public health evidence on addiction and mental health risks. SAM has indicated it may pursue legal challenges to the final rule.

Legal and Regulatory Framework

The intersection of the Controlled Substances Act scheduling system and Internal Revenue Code Section 280E creates a complex legal framework where administrative drug policy directly determines tax treatment for an entire industry.

Controlled Substances Act Scheduling Criteria

The CSA establishes five schedules with distinct criteria. Schedule I requires: (1) high potential for abuse, (2) no currently accepted medical use in treatment in the United States, and (3) lack of accepted safety for use under medical supervision. Schedule III requires: (1) lower potential for abuse than Schedule I or II substances, (2) currently accepted medical use, and (3) moderate or low potential for physical dependence or high potential for psychological dependence. The Attorney General may reschedule substances through rulemaking under 21 U.S.C. § 811(a), following the notice-and-comment procedures of the Administrative Procedure Act. The DEA must request a scientific and medical evaluation from HHS, which is binding on the scheduling factors related to medical use, abuse potential, and safety.

Section 280E Statutory Language

The full text of 26 U.S.C. § 280E states: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted." The statute contains no exception for state-legal activity. "Trafficking" is defined by reference to the CSA, which prohibits manufacture, distribution, and possession with intent to distribute controlled substances. The phrase "schedule I and II" is critical: Schedule III substances are explicitly excluded from Section 280E's prohibition, meaning rescheduling automatically eliminates the tax penalty without requiring congressional action.

Tax Court Precedent

Multiple Tax Court decisions have shaped 280E application. In Olive v. Commissioner, 139 T.C. 19 (2012), the court held that a medical cannabis dispensary operating legally under California law could not deduct rent, payroll, or other operating expenses, but could deduct cost of goods sold. The court rejected arguments that state law compliance removed the business from 280E's scope. In Alterman v. Commissioner, T.C. Memo 2018-83, the court addressed whether a dispensary selling cannabis and non-cannabis products (pipes, clothing, CBD products) could allocate expenses between the two business lines. The court held that if cannabis sales constitute the primary business, all expenses are subject to 280E, even those allocable to legal product sales. This "primary business" test has been applied inconsistently across cases. In Patients Mutual Assistance Collective Corp. v. Commissioner, T.C. Memo 2015-213, the court allowed a cannabis business to deduct expenses for a separate caregiving business line that provided services to patients, finding the caregiving operation was a distinct trade or business not consisting of trafficking.

Administrative Procedure Act Requirements

The DEA's rescheduling process must comply with the Administrative Procedure Act's requirements for informal rulemaking under 5 U.S.C. § 553. The agency must publish a notice of proposed rulemaking, provide opportunity for public comment, consider all significant comments, and issue a final rule with a statement of basis and purpose. Legal challenges to the final rule would be filed in federal court of appeals under 21 U.S.C. § 877, which provides for direct review of DEA scheduling decisions. Challengers must demonstrate that the rule is arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law under the APA standard.

State-by-State Breakdown

Federal rescheduling and 280E reform will affect cannabis businesses differently across states based on each jurisdiction's tax structure, regulatory maturity, and market dynamics.

California

California's cannabis market generated $5.3 billion in sales in 2025, the nation's largest. The state imposes a 15 percent excise tax on retail sales plus standard sales tax, generating $1.1 billion in state revenue. California cannabis businesses currently face effective federal tax rates of 70 to 80 percent due to 280E. 280E elimination could reduce California wholesale prices by 25 to 30 percent as cultivators and manufacturers gain tax efficiency, potentially decreasing state excise tax collections by $200 million to $300 million annually unless the state adjusts its tax rate. The California Department of Tax and Fee Administration has not announced plans to modify the excise tax structure in response to federal rescheduling. California allows cannabis businesses to deduct ordinary business expenses for state income tax purposes, creating a split treatment where businesses pay federal tax on gross profit but state tax on net income. Rescheduling will align federal and state treatment.

Florida

Florida operates a medical-only cannabis program with 24 licensed operators and 850+ dispensaries serving 880,000 registered patients. The state imposes no excise tax on medical cannabis, collecting only standard sales tax. Florida has no state income tax, so 280E elimination provides no state-level benefit but will significantly improve operator profitability. Trulieve controls approximately 50 percent of Florida's market. The company reported that Florida operations generated $850 million in revenue in 2025 with federal tax liability of $204 million. Rescheduling could add $120 million to Trulieve's annual Florida net income, according to the company's investor presentations. Florida voters will decide on adult-use legalization in November 2026. If approved, the state would become the largest adult-use market in the Southeast, with projected sales of $4 billion to $6 billion annually by 2028.

New York

New York launched adult-use sales in December 2022, with 150+ licensed dispensaries operating by May 2026. The state imposes a 13 percent excise tax plus a potency-based tax on cultivators. New York collected $180 million in cannabis tax revenue in 2025. New York allows cannabis businesses to deduct ordinary expenses for state corporate tax purposes, similar to California. The state's high operating costs—retail rents averaging $15,000 to $30,000 monthly in New York City—make 280E elimination particularly impactful. Industry analysts estimate that New York operators currently pay 65 to 75 percent effective federal tax rates, among the highest in the nation.

Illinois

Illinois generated $1.8 billion in adult-use cannabis sales in 2025, with a tiered excise tax structure: 10 percent on cannabis flower, 20 percent on edibles, and 25 percent on concentrates. The state collected $445 million in cannabis tax revenue. Illinois does not allow cannabis businesses to deduct ordinary expenses for state income tax purposes, instead requiring businesses to add back federally disallowed deductions. This creates double taxation: businesses pay federal tax on gross profit and state tax on the same gross profit. Rescheduling will eliminate the federal burden but Illinois businesses will continue facing state-level 280E treatment unless the legislature amends state tax law. The Illinois Department of Revenue has not indicated whether it will conform to federal rescheduling for state tax purposes. Several other states including Massachusetts and New Jersey have similar state-level 280E provisions that will require legislative action.

Ohio

Ohio voters approved adult-use legalization in November 2023, with sales launching in August 2024. The state imposes a 10 percent excise tax on adult-use sales while medical sales remain tax-exempt. Ohio collected $95 million in cannabis tax revenue in the program's first nine months. Ohio allows cannabis businesses to deduct ordinary expenses for state commercial activity tax purposes. The state's relatively new market means most operators are not yet profitable, limiting the immediate impact of 280E elimination. However, as the market matures and operators achieve profitability in 2026-2027, federal tax savings will become significant.

Michigan

Michigan's adult-use market generated $3.1 billion in sales in 2025, the nation's third-largest. The state imposes a 10 percent excise tax plus 6 percent sales tax, collecting $496 million in cannabis tax revenue. Michigan allows unlimited licenses, creating intense competition and driving wholesale flower prices to $800-$1,200 per pound, among the nation's lowest. Michigan's competitive market means 280E elimination will flow primarily to consumers through lower prices rather than operator profits. Industry analysts project retail prices could decline 20 to 25 percent within 12 months of rescheduling as operators pass tax savings to consumers to maintain market share.

Massachusetts

Massachusetts generated $1.9 billion in adult-use sales in 2025, with a 10.75 percent excise tax plus up to 3 percent local option tax and 6.25 percent sales tax. The state collected $244 million in cannabis excise tax revenue. Massachusetts enacted state-level Section 280E language in its cannabis tax statute, requiring businesses to add back federally disallowed deductions for state tax purposes. The Massachusetts Cannabis Control Commission has recommended that the legislature repeal this provision in light of federal rescheduling, but no bill has been filed as of May 2026.

Market and Business Implications

The elimination of Section 280E will fundamentally restructure cannabis industry economics, shifting billions of dollars from federal tax liability to operator profitability, consumer savings, and competitive repositioning.

Immediate Financial Impact on Operators

Multi-state operators will see the most dramatic financial improvement. A typical MSO with $500 million in annual revenue, $350 million in COGS, and $100 million in operating expenses currently pays federal tax on $150 million in profit (revenue minus COGS only). At a 21 percent corporate rate, the tax liability is $31.5 million. After rescheduling, the same MSO will pay tax on $50 million in net income (revenue minus COGS and operating expenses), resulting in $10.5 million in tax liability—a $21 million annual savings. For the 15 largest MSOs, aggregate annual tax savings are projected at $800 million to $1.2 billion, according to cannabis financial analysts at Viridian Capital Advisors. This capital will flow to debt reduction, expansion investment, acquisitions, and shareholder returns. Single-state operators and small businesses will see proportionally larger benefits. A dispensary with $3 million in revenue, $1.8 million in COGS, and $900,000 in operating expenses currently pays $252,000 in federal tax (21 percent of $1.2 million gross profit). After rescheduling, the same dispensary will pay $63,000 in tax (21 percent of $300,000 net income)—a $189,000 savings representing 6.3 percent of revenue.

Wholesale and Retail Pricing Dynamics

Tax savings will flow through the supply chain differently depending on market structure and competition intensity. In mature, competitive markets like Michigan, Colorado, and Oregon, pricing pressure will force operators to pass most tax savings to consumers. In limited-license markets like New York, Illinois, and Florida, operators may retain more savings as profit. Wholesale cultivators will see the largest per-unit impact. A cultivator producing 10,000 pounds annually at $1,500 per pound average wholesale price generates $15 million in revenue. With $8 million in COGS and $4 million in operating expenses, current federal tax liability is $1.47 million (21 percent of $7 million gross profit). After rescheduling, tax liability drops to $630,000 (21 percent of $3 million net income)—a $840,000 savings, or $84 per pound. Industry analysts project wholesale flower prices will decline 15 to 20 percent within six months of rescheduling as cultivators compete for market share using their tax savings. Retail prices typically lag wholesale changes by 60 to 90 days as inventory turns over.

Capital Markets and Valuation

Public cannabis company valuations have already begun reflecting anticipated 280E elimination. The MSOS ETF, tracking the largest U.S. MSOs, increased 47 percent between October 2022 (when President Biden announced the scheduling review) and May 2026. Curaleaf's stock price increased 89 percent over the same period. Equity analysts have revised price targets upward based on improved profitability projections. Curaleaf's consensus 12-month price target increased from $4.50 in October 2022 to $11.25 in May 2026, implying a market capitalization increase of $2.3 billion. Across the 15 largest MSOs, aggregate market capitalization increased $8.7 billion during this period. Debt markets have also responded. Cannabis operators have historically paid 12 to 18 percent interest on senior secured debt due to federal illegality and 280E-driven cash flow uncertainty. Following the DEA's final rule announcement, several MSOs refinanced existing debt at rates of 8 to 10 percent, saving $40 million to $60 million annually in interest expense across the industry. Private equity and institutional investors have increased cannabis allocations in anticipation of improved unit economics. Institutional ownership of MSO stocks increased from 4 percent of shares outstanding in 2022 to 14 percent in May 2026, according to Viridian Capital Advisors.

Competitive Dynamics and Market Consolidation

280E elimination will accelerate market consolidation by improving the financial viability of acquisition targets and providing acquirers with greater capital for deals. MSOs have been constrained in M&A activity by limited free cash flow after tax obligations. With tax burdens reduced by 60 to 70 percent, operators will have substantially more capital for acquisitions. Small operators struggling with 280E compliance will become attractive acquisition targets. A single-location dispensary with $2 million in annual revenue but minimal profitability due to tax burden becomes significantly more valuable when the acquirer can realize $150,000 to $200,000 in annual tax savings post-acquisition. Vertical integration strategies may shift. Under 280E, vertical integration provided tax advantages by maximizing COGS through cultivation and manufacturing operations. After rescheduling, this advantage disappears, potentially making specialized single-function operators (cultivators, manufacturers, or retailers) more competitive. However, vertical integration provides other benefits including supply chain control and margin capture that will likely sustain the model.

Ancillary Business Impact

Cannabis accounting, tax, and legal service providers will see reduced demand for 280E compliance work but increased demand for tax planning, amended return preparation, and restructuring advice. The cannabis tax accounting sector, estimated at $150 million annually, will need to pivot to general business advisory services. Software providers offering 280E-specific inventory accounting and expense tracking features will need to update products. Companies including Flowhub, Dutchie, and BioTrack have built 280E compliance into their point-of-sale and ERP systems. Real estate investors and landlords may see increased demand as cannabis operators expand using tax savings. However, property owners in states with high cannabis business density may face pressure to reduce rents as operators gain negotiating leverage from improved cash flow.

What Experts Say

Tax practitioners, industry analysts, and policy experts have provided detailed assessments of rescheduling's implications, with consensus that 280E elimination represents the most significant financial development in cannabis industry history. Andrew Hunzicker, a cannabis tax attorney at Dykema Gossett who has represented operators in dozens of IRS audits, stated in a May 2026 client advisory that rescheduling will "fundamentally transform cannabis business economics overnight." According to Hunzicker, the biggest challenge will be transition planning, as businesses must decide whether to amend prior-year returns for years still open under the statute of limitations or focus on prospective tax savings. Rachel Gillette, executive director of Colorado's Cannabis Business Alliance, told the Denver Post that 280E elimination will "level the playing field between cannabis and other industries, allowing operators to compete on product quality and customer service rather than tax survival." Gillette noted that Colorado's mature market means most savings will flow to consumers through lower prices rather than operator profits. Morgan Fox, political director of the National Organization for the Reform of Marijuana Laws, described rescheduling as "a major step forward but not the finish line." According to Fox, Schedule III classification still leaves cannabis federally controlled, maintaining barriers to interstate commerce, FDA regulation, and full banking access. NORML continues advocating for complete descheduling through congressional action. Dr. Staci Gruber, director of the Marijuana Investigations for Neuroscientific Discovery program at McLean Hospital, told the Boston Globe that rescheduling reflects "the growing body of scientific evidence supporting cannabis's therapeutic applications." Gruber noted that Schedule III classification will facilitate additional research by reducing regulatory barriers to clinical trials. Kevin Sabet, president of Smart Approaches to Marijuana, told Fox News that the DEA's decision "ignores the public health evidence on cannabis's addiction potential and mental health risks." According to Sabet, rescheduling will lead to increased youth access and normalization of cannabis use. SAM is evaluating legal challenges to the final rule. Emily Paxhia, co-founder of Poseidon Investment Management, told Bloomberg that 280E elimination will "unlock $2 billion to $3 billion in annual cash flow for the industry, creating a wave of M&A activity and expansion investment." Paxhia projected that cannabis industry employment will increase 25 to 30 percent over the next three years as operators expand using tax savings.

What's Next

The July 1, 2026 effective date for Schedule III classification triggers a complex implementation timeline involving IRS guidance, potential legal challenges, state legislative responses, and operator tax planning decisions.

IRS Guidance and Implementation

The Internal Revenue Service must issue guidance clarifying how businesses should implement 280E elimination. Key questions include: -